Pharmacodynamic study of sunitinib malate in patients with renal cell cancer and other advanced solid malignancies.

Trial Profile

Pharmacodynamic study of sunitinib malate in patients with renal cell cancer and other advanced solid malignancies.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Renal cancer; Renal cell carcinoma; Solid tumours
  • Focus Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 15 May 2013 Planned end date changed from 1 Mar 2008 to 1 Jul 2013 as reported by ClinicalTrials.gov record.
    • 15 May 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top